These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 38375101)

  • 1. Microbiota-Based Live Biotherapeutic Products for
    Monday L; Tillotson G; Chopra T
    Infect Drug Resist; 2024; 17():623-639. PubMed ID: 38375101
    [No Abstract]   [Full Text] [Related]  

  • 2. Microbiota restoration therapies for recurrent
    DuPont HL; DuPont AW; Tillotson GS
    Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the gut microbiome in colonization resistance and recurrent
    Seekatz AM; Safdar N; Khanna S
    Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live Biotherapeutic Products for the Prevention of Recurrent
    Pettit NN; Shaeer KM; Chahine EB
    Ann Pharmacother; 2024 Dec; 58(12):1204-1217. PubMed ID: 38546138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
    Nagarakanti S; Orenstein R
    Infect Drug Resist; 2023; 16():3137-3143. PubMed ID: 37235073
    [No Abstract]   [Full Text] [Related]  

  • 6. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
    Lavoie T; Appaneal HJ; LaPlante KL
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
    Orenstein R
    Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
    Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
    Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent
    Stallhofer J; Steube A; Katzer K; Stallmach A
    Visc Med; 2024 Apr; 40(2):82-91. PubMed ID: 38584858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota changes associated with
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.
    Ke S; Gálvez JAV; Sun Z; Cao Y; Pollock NR; Chen X; Kelly CP; Liu YY
    J Infect Dis; 2024 Sep; ():. PubMed ID: 39316685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection.
    Hunt A; Drwiega E; Wang Y; Danziger L
    Am J Health Syst Pharm; 2024 Jul; 81(15):e402-e411. PubMed ID: 38470061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent
    Wang Y; Hunt A; Danziger L; Drwiega EN
    Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786164
    [No Abstract]   [Full Text] [Related]  

  • 14. Systematic review of the orally administered microbiome therapeutic, fecal microbiota spores, live-brpk, to prevent recurrence of
    LaPlante K; Stevens R; Gonzales-Luna AJ
    SAGE Open Med; 2024; 12():20503121241274192. PubMed ID: 39386261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human microbiome: Impact of newly approved treatments on C. difficile infection.
    Bland CM; Love BL; Jones BM
    Am J Health Syst Pharm; 2024 Sep; ():. PubMed ID: 39230353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial ecology between
    Kamiya S
    Biosci Microbiota Food Health; 2023; 42(4):229-235. PubMed ID: 37791342
    [No Abstract]   [Full Text] [Related]  

  • 17. Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent
    Berry P; Khanna S
    Future Microbiol; 2024; 19(18):1519-1528. PubMed ID: 39320321
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
    Pipek B; Valentová H; Fojtík P; Urban O
    Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence.
    Gonzales-Luna AJ; Carlson TJ; Garey KW
    Clin Infect Dis; 2023 Dec; 77(Suppl 6):S487-S496. PubMed ID: 38051970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.